SCHEMBL2589475

SCHEMBL2589475

NC(=O)N(S)c1cccc(Cl)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
ALDH1A1 P00352 3/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
PNMT P11086 1/20 0.35
ADRA2A P08913 2/20 0.35
S100B P04271 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGAV P06756 1/20 0.35
CYP3A4 P08684 1/20 0.35
HTR1A P08908 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
MAOA P21397 1/20 0.35
ADRA1D P25100 1/20 0.35
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265387 0.85 CES2 (0.39) TSHRALDH1A1LMNAKDM4EKMT2A
SCHEMBL11419915 0.79 TSHR (0.42) TSHRALDH1A1LMNAKDM4EKMT2A
SCHEMBL3264512 0.79 ALDH1A1 (0.40) TSHRALDH1A1LMNAKMT2AMEN1
SCHEMBL14053556 0.78 ALDH1A1 (0.40) TSHRALDH1A1KDM4EKMT2AMEN1
SCHEMBL17513254 0.78 TSHR (0.41) TSHRALDH1A1LMNAKDM4EKMT2A
SCHEMBL8008925 0.78 TSHR (0.41) TSHRALDH1A1LMNAKDM4EKMT2A
SCHEMBL11541466 0.77 TSHR (0.38) TSHRALDH1A1LMNAKMT2AMEN1
SCHEMBL19384332 0.74 TP53 (0.43) TSHRALDH1A1LMNAKMT2AMEN1
SCHEMBL28498195 0.74 ALDH1A1 (0.41) TSHRALDH1A1LMNAKDM4EKMT2A
SCHEMBL10780634 0.73 TSHR (0.44) TSHRALDH1A1LMNAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926719-B1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-05-31 EP disclosed
US-9388175-B2 2-aniline-4-aryl substituted thiazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2016-07-12 US disclosed
US-20110269748-A1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2011-11-03 US disclosed
EP-1926719-A2 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-04 EP disclosed
WO-2007031440-A2 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269748-A1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES CHRNA4, CHRNA5, CHRNA7 TSHR 607/4885ALDH1A1 582/4885LMNA 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.